Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Takamatsu Y, Sunami K, Muta T, Morimoto H, Miyamoto T, Higuchi M, Uozumi K, Hata H, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: miyamoto t. Int J Hematol. 2013 Aug;98(2):179-85. doi: 10.1007/s12185-013-1389-6. Epub 2013 Jul 6. Int J Hematol. 2013. PMID: 23832805 Clinical Trial.
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Miyamoto T, Yoshimoto G, Kamimura T, Muta T, Takashima S, Ito Y, Shiratsuchi M, Choi I, Kato K, Takenaka K, Iwasaki H, Takamatsu Y, Teshima T, Akashi K. Miyamoto T, et al. Int J Hematol. 2013 Sep;98(3):337-45. doi: 10.1007/s12185-013-1402-0. Epub 2013 Jul 23. Int J Hematol. 2013. PMID: 23877150 Clinical Trial.
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Takashima S, Miyamoto T, Kadowaki M, Ito Y, Aoki T, Takase K, Shima T, Yoshimoto G, Kato K, Muta T, Shiratsuchi M, Takenaka K, Iwasaki H, Teshima T, Kamimura T, Akashi K. Takashima S, et al. Among authors: miyamoto t. Int J Hematol. 2014 Aug;100(2):159-64. doi: 10.1007/s12185-014-1611-1. Epub 2014 Jun 14. Int J Hematol. 2014. PMID: 24928523
Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma.
Mori Y, Choi I, Yoshimoto G, Muta T, Yamasaki S, Tanimoto K, Kamimura T, Iwasaki H, Ogawa R, Akashi K, Miyamoto T; Fukuoka Blood and Marrow Transplantation Group. Mori Y, et al. Among authors: miyamoto t. Int J Hematol. 2020 May;111(5):673-680. doi: 10.1007/s12185-020-02833-w. Epub 2020 Jan 24. Int J Hematol. 2020. PMID: 31981096 Clinical Trial.
A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT). Fuchida SI, et al. Among authors: miyamoto t. Int J Hematol. 2019 Jan;109(1):107-114. doi: 10.1007/s12185-018-2543-y. Epub 2018 Oct 4. Int J Hematol. 2019. PMID: 30284685 Clinical Trial.
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K. Sunami K, et al. Among authors: miyamoto t. Int J Clin Oncol. 2019 Aug;24(8):966-975. doi: 10.1007/s10147-019-01436-8. Epub 2019 Apr 1. Int J Clin Oncol. 2019. PMID: 30937622 Clinical Trial.
Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).
Murayama T, Fukuda T, Okumura H, Sunami K, Sawazaki A, Maeda Y, Tsurumi H, Uike N, Hidaka T, Takatsuka Y, Eto T, Tsuda H, Fujisaki T, Miyamoto T, Tsuneyoshi N, Iyama S, Nagafuji K, Harada M. Murayama T, et al. Among authors: miyamoto t. Int J Hematol. 2016 Jun;103(6):676-85. doi: 10.1007/s12185-016-1976-4. Epub 2016 Mar 21. Int J Hematol. 2016. PMID: 27084252 Clinical Trial.
Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Kato K, Takenaka K, Iwasaki H, Eto T, Takamatsu Y, Teshima T, Akashi K; Fukuoka Blood and Marrow Transplant Group (FBMTG). Muta T, et al. Among authors: miyamoto t. Intern Med. 2013;52(1):63-70. doi: 10.2169/internalmedicine.52.8390. Epub 2013 Jan 1. Intern Med. 2013. PMID: 23291675 Free article.
4,202 results